Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05177666
Other study ID # V1
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date December 30, 2021
Est. completion date March 30, 2024

Study information

Verified date December 2021
Source The University of Hong Kong-Shenzhen Hospital
Contact Zhiyuan Xu, MD
Phone +86-18307555170
Email xuzy@hku-szh.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a prospective registration study for patients with advanced refractory solid tumors. Patients who meet the eligibility criteria will be included to participate in the study, and baseline information to be collected after signed informed consent. Patients will choose for themselves whether to carry out targeted therapy or other appropriate treatment methods. And we plan to follow up for at least 12 months or until disease progression or death.


Description:

1. Screen and enroll 120 patients with refractory solid tumors, and sign informed consents; 2. Extract the clinical data, including gender, age, disease diagnosis, past treatment history and genetic test results, etc.; 3. Take biopsy samples and perform NGS testing on patients. After discussion by the Molecular Steering Committee (MTB), the recommendations for treatment guidance will be given based on treatment guidelines and clinical experience; 4. The patient and the clinician jointly select the treatment plan and follow-up until the patient's disease progresses. The follow-up time will be 1 year; 5. During the follow-up period, clinical treatment and routine examination information of patients will be collected; 6. If the patient fails to receive molecular targeted therapy or they cannot tolerate the adverse reaction of the drug after adequate treatment, the clinician will evaluate whether a second NGS resistance test is needed or the participant may withdraw from the study.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 120
Est. completion date March 30, 2024
Est. primary completion date December 30, 2023
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Recurrent or metastatic malignant solid tumor confirmed by histology or cytology - Disease progression or intolerance after receiving standard treatment - With evaluable lesions (RECIST 1.1 standard) - Tumor tissue pieces with sufficient formalin-fixed paraffin-embedded (FFPE) can be used for genetic testing - ECOG PS score 0-4 (3-4 points only for patients with tumor burden) - Sign the informed consent form Exclusion Criteria: - The subject is participating in any other clinical research; - Researchers believe that serious or uncontrolled medical diseases (ie uncontrolled diabetes, chronic kidney disease, chronic lung disease, or uncontrolled active infections, mental illnesses/social conditions that restrict compliance with research requirements) that will confuse the analysis of research treatment response ; - Patients during pregnancy or lactation

Study Design


Intervention

Drug:
Targeted therapy
Based on next-generation sequencing (NGS) detection, after discussion by the Molecular Steering Committee (MTB), intervention guidance suggestions are given based on domestic and foreign guidelines and clinical experience, and finally the patient and clinician jointly choose the treatment plan.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
The University of Hong Kong-Shenzhen Hospital Tianjin Happy Life Technology Co., Ltd.

References & Publications (10)

Abrahams E, Eck SL. Molecular medicine: Precision oncology is not an illusion. Nature. 2016 Nov 17;539(7629):357. doi: 10.1038/539357e. — View Citation

Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013 Oct;45(10):1127-33. doi: 10.1038/ng.2762. — View Citation

Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Den — View Citation

Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MDM, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, Chu A, Margolin AA, Van't Veer LJ, Lopez-Bigas N, Laird PW, Raphael BJ, Ding L, Robertson AG, By — View Citation

Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Massiani MA, Mauborgne C, Armanet S, Servant N, Bièche I, Bernard V, Gentien D, Jezequel P, Attignon V, Boyault S, Vincent-Salomon A, Servois V, Sablin MP, Kamal — View Citation

Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, Wagle N, Stenzinger A, Bonastre J, Bayle A, Michiels S, Bièche I, Rouleau E, Jezdic S, Douillard JY, Reis-Filho JS, Dienstmann R, André F. — View Citation

Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, Kesari S, Helsten TL, Bazhenova LA, Romero J, Fanta PT, Lippman SM, Kurzrock R. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Mol Cancer Ther. 2016 Apr;15(4):743 — View Citation

Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cance — View Citation

Von Hoff DD, Stephenson JJ Jr, Rosen P, Loesch DM, Borad MJ, Anthony S, Jameson G, Brown S, Cantafio N, Richards DA, Fitch TR, Wasserman E, Fernandez C, Green S, Sutherland W, Bittner M, Alarcon A, Mallery D, Penny R. Pilot study using molecular profiling — View Citation

Wheler J, Lee JJ, Kurzrock R. Unique molecular landscapes in cancer: implications for individualized, curated drug combinations. Cancer Res. 2014 Dec 15;74(24):7181-4. doi: 10.1158/0008-5472.CAN-14-2329. Epub 2014 Oct 17. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Changes in ECOG score before and after treatment We compare the ECOG scores of each visit with the baseline, including the number and proportion, and the difference. 2021.11-2023.11
Other Proportion of targeted therapy guided by second tumor molecular characteristics After targeted therapy drug resistance, then the proportion of targeted therapy guided by the second tumor molecular characteristics would be calculated during study period. 2021.11-2023.11
Primary Objective Response Rate (ORR) ORR is judged based on RECIST 1.1 criteria for all treatment groups at each visit period. 2021.11-2023.11
Primary Proportion of targeted therapy guided by tumor molecular characteristics The proportion of all enrolled patients receiving targeted therapy guided by tumor molecular characteristics during the study period, would be calculated, which defined as having received one or more the treatments based on tumor molecular characteristics. 2021.11-2023.11
Secondary Progression-free survival (PFS) PFS is defined as the time from the first administration to disease progression or death. 2021.11-2023.11
Secondary Overall survival (OS) OS is defined as the time from the first administration to death from any cause. 2021.11-2023.11
Secondary Best overall response (BOR) The effectiveness of a patient would be evaluated multiple times, and the best one is defined as the best overall response. 2021.11-2023.11
Secondary Adverse events The incidence of serious adverse events in each group, which is judged based on CTCAE v5.0 standard. 2021.11-2023.11
Secondary Quality of Life Score (QoL) The QoL is evaluated by the scale (0PROMIS-29 Profile v2.1) at each visit period for all the enrolled patients. 2021.11-2023.11
Secondary Proportion of patients with intervening genomic variants The intervening genomic variants are defined by the conclusion after MTB discussion. 2021.11-2023.11
See also
  Status Clinical Trial Phase
Recruiting NCT05073744 - Nalbuphine Versus Morphine for Perioperative Tumor Ablation Phase 4
Completed NCT03969641 - Safety of RIV4 Versus IIV4 in Pregnant Women Phase 4
Completed NCT05592951 - Safety and Tolerability of a Novel Amino-acid Based Hydration Drink in Healthy Volunteers N/A
Completed NCT04693429 - Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+ Phase 1
Completed NCT01636024 - To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594 Phase 1
Completed NCT01415102 - A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372. Phase 1
Completed NCT01243502 - A Study to Assess the Pharmacokinetics, Safety and Tolerability of CT327 in Healthy Male Volunteers Phase 1
Completed NCT06072170 - Single Ascending Doses of Kratom in Healthy Nondependent Adults With Opioid Experience Phase 1
Completed NCT05076253 - Efficacy of Ivermectin in COVID-19 Phase 1/Phase 2
Recruiting NCT06060379 - Giochiamo 626 - Gaming for Health and Safety in Workplaces N/A
Recruiting NCT05298800 - Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23 Phase 4
Completed NCT05188638 - Safety of Ascending Single and Multiple Doses of Nebulised SoftOx Inhalation Solution in Healthy Subjects Phase 1
Completed NCT05145621 - Oral Bio-equivalence Study Phase 1
Recruiting NCT05580159 - New Generation mRNA Booster Vaccine Against Emerging VOCs Phase 3
Not yet recruiting NCT04596956 - Safety and Efficacy of Sodium Bicarbonate Ringer Injection Phase 4
Completed NCT03033329 - Single Dose Escalation and Multiple Dose Escalation Trial of an Intravenous Formulation of MRX-4 Phase 1
Terminated NCT01929811 - NeoMET Study in Neoadjuvant Treatment of Breast Cancer Phase 2
Completed NCT01193335 - Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants. Phase 4
Completed NCT03300466 - A Study to Evaluate the Performance and Safety of GP0045 for Correction of Moderate to Severe Nasolabial Folds N/A
Active, not recruiting NCT05686161 - mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs Phase 3